References
- Plewig G, Jansen T. Seborrheic dermatitis. Fitzpatrick’s Dermatology in General Medicine (7th Edition). McGraw-Hill, NY, USA, 219–225 (2008).
- Gupta AK, Chow M. Pimecrolimus: a review. J. Eur. Acad Dermatol. Venerol.17(5), 493–503 (2003).
- Warshaw EM, Wohlhuter RJ, Liu A et al. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J. Am. Acad. Dermatol.57, 257–264 (2007).
- Schwartz RA, Janusz CA et al. Seborrheic dermatitis: an overview. Am. Fam. Phys.74(1), 125–130 (2006).
- Bikowsky J. Facial seborrheic dermatitis: a report on current status and therapeutic horizons. J. Drugs Dermatol.8(2), 125–133 (2009).
- Gupta AK, Madzia SE, Batra R. Etiology and management of seborrheic dermatitis. Dermatology208(2), 89–93 (2004).
- Brownell I, Quan LT, Hsu S. Topical pimecrolimus in the treatment of seborrheic dermatitis. Dermatol. Online J.9(3), 13 (2003).
- Cook BA, Warshaw EM. Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis. Am. J. Clin. Dermatol.10(2), 103–118 (2009).
- Eichenfield LF, Lucky AW, Boguniewicz M et al. Safety and efficacy of pimecrolimus 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J. Am. Acad. Dermatol.46(4), 495–504 (2002).
- Wollina U. The role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis. Am. J. Clin. Dermatol.8(3), 157–173 (2007).
- Billich A, Aschauer H, Aszódi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int. J. Pharmaceut.269, 29–35 (2004).
- Tatlican S, Eren C, Oktay B et al. Experience with repetitive use of pimecrolimus: exploring the effective and safe use in the treatment of relapsing seborrheic dermatitis. J. Dermatol. Treat.20(3), 1–3 (2009).
- Sugita T, Tajima M. A new calcineurin inhitibor, pimecrolimus, inhibits the growth of malassezia spp. Antimicrob. Agents Chemother.50(8), 2897–2898 (2006).
- Cunha PR. Pimecrolimus cream 1% is effective in seborrheic dermatitis refractory to treatment with topical corticosteroids. Acta Dermatol. Venereol.86, 69–70 (2006).
- Rallis E, Nasiopoulou A, Kouskoukis C, Koumantaki E. Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk. Drugs Exp. Clin. Res.5/6, 191–195 (2005).
- de Moraes AP, de Arruda EAG, Vitoriano MAV et al. An open-label efficacy pilot study with pimecrolimus cream 1% in adults with facial seborrhoeic dermatitis infected with HIV. J. Eur. Acad. Dermatol. Venerol.21(5), 596–601 (2007).
- High WA, Pandya AG. Pilot trial of 1% pimecrolimus cream in the treatment of seborrheic dermatitis in African American adults with associated hypopigmentation. J. Am. Acad. Dermatol.54, 1083–1088 (2006).
- Firooz A, Solhpour A, Gorouhi F et al. Pimecrolimus cream, 1%, vs. hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch. Dermatol.142, 1066–1067 (2006).
- Koc E, Arca E, Kose O, Akar A. An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis. J. Dermatol. Treat.2(1), 4–9 (2009).
- Cicek D, Kandi B, Bakar S, Turgut D. Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of seborrhoeic dermatitis: a randomized clinical study. J. Dermatol. Treat.20(2), 1–6 (2009).
- Kim BS, Kim SH, Kim MB et al. Treatment of facial seborrheic dermatitis with pimecrolimus cream 1%: an open-label clinical study in Korean patients. J. Korean Med. Sci.22(5), 868–872 (2007).
- Rigopoulos D, Ioannides D, Kalogeromitros D, Gregoriou S, Katsambas A. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrheic dermatitis. A randomized open-label clinical trial. Br. J. Dermatol.151, 1071–1075 (2004).